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Abstract : Formation of new blood vessels is required for normal embryonic development and healing of damaged
tissues, but also is essential for tumor growth. Although CD34+VEGF-R2(KDR)+ endothelial progenitor cells and
CD14+ monocytes in human peripheral blood are known to actively participate in angiogenesis and vasculogenesis,
the clear role of monocytes in the process of neovascularization is matter of debate. Here, we investigated whether
a combination of two types of cells shows synergism in tumor-induced neovascularization. Fluorescently labeled
purified CD34+ HSCs, CD14+ monocytes or combination of CD34+ HSCs and CD14+ monocytes were intratumor-
ally injected into nude mice bearing human tumor of pancreatic adenocarcinoma. CD14+ monocytes or combination
of CD34+ HSCs and CD14+ monocytes. Injection of a mixture of the 2 subsets resulted in improved neovasculariza-
tion in vivo to any single-cell-type transplantation. These data demonstrate that human CD14+ monocytes as well as
CD34+ HSCs can differentiate along the endothelial lineage in a specific permissive environment and thus this com-
bination represent an autologous transplantable cell source for therapeutic neovasculogenesis. 
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1. Introduction
New blood vessel formation, or neovascularization, is
required for normal embryonic development and promotes
healing process of damaged or injured tissues and organs. In
addition, the finding that neovascularization also promotes
tumor growth and inflammatory diseases
1 makes endothelial
progenitor cells (EPCs) of great clinical interest. Through the
investigation of participating components and development of
model system, the elucidation of the underlying cellular and
molecular mechanisms of neovasularization made a noticeable
progress. However, controversies over the identity of
circulating EPCs have not completely resolved which cells give
rise to endothelial cells during in vivo angiogenesis. 
The first EPCs were described as CD34
+enriched mononuclear
cells that acquired endothelial surface marker expression in
culture.
2 CD34 is a marker of hematopoietic stem cells (HSCs)
and is expressed by less than 0.1 % of circulating peripheral
blood mononuclear cells or 1% of cord blood mononuclear
cells.3 Subsequent studies revealed that a subpopulation of
circulating CD34+ cells expressing VEGF-R2+ could form
endothelial colonies in vitro.4-5 Only a fraction of these cultured
cells incorporated acetylated DiI, expressed several markers in
common with endothelial cells such as CD34, CD31 and
VEGF-R2.
4 Studies have shown that purified human CD34+
cells can integrate into the vasculature of murine models.6-7 On
the contrary, Fernandez-Pujol et al.
8 demonstrated that CD14+
cells differentiate into endothelial cell-like cells exhibiting
characteristics of both endothelial cells and monocytes under
appropriate in vitro conditions. Monocytes, circulating and non-
proliferating cells in a steady state, play an important role in
immune defense, inflammation, and tissue remodeling and they
do so by phagocytosis, antigen processing and presentation, and
by cytokine production.
9 They can differentiate into dendritic
cells during inflammation and thereby playing key roles in
linking innate immunity to adaptive immunity.
10 Apart from
these immunological roles, CD14
+ Monocytes coexpress
endothelial and myeloid lineage markers and form vessel-like
structure in vitro.
11-12 Furthermore, these cells have capacity to
integrate into the vasculature of ischemic tissue in non-diabetic
mice.
13-14 Myeloid to endothelial plasticity in vivo was shown
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recently through adoptive transfer of immature myeloid
progenitors in mice and subsequently confirmed by vessels
with donor origin myeloid cells in the liver.
15 In addition, recent
reports have also identified a myeloid/endothelial biphenotypic
leukocyte population within mouse and human tumors. Thus, it
appears that there are two classes of human circulating
endothelial progenitor cells, CD34
+ and CD34-CD14+ cells.
While attention has focused on CD34
+ cells, CD34-CD14+
monocytes are far more abundant16 and may represent the most
common class of circulating EPCs 
Studies have shown that vascular network in tumor is
associated with recruitment of hematopoietic and circulating
endothelial precursor cells.
11 However, little is known about the
combined effect of freshly isolated monocytes and CD34
+ HSC
on tumor angiogenesis in vivo. This study examined whether
CD14
+ cells actually differentiate and integrate into the
vasculature in vivo and whether they synergize with CD34
+
HSC in neovascularization. 
2. Materials and Methods
2.1 Purification of Mononuclear Cells and Isolation of
CD34
+
 HSCs and CD14
+
 Monocytes
The study protocol was approved by the Institutional Review
Board of Severance Hospital (Severance Hospital, Yonsei
University Health System, Seoul, Korea). Peripheral blood
(50 mL) was obtained from healthy donors following informed
consent. Mononuclear cells were fractionated from other
components of peripheral blood by centrifugation on Ficol-
Hypaq density gradient centrifugation (Pharmacia Biotech,
Uppsala, Sweden). CD34
+ cells were isolated using standard
immunomagnetic techniques (CD34 isolation Kit, MACS;
Miltenyi Biotech, Auburn, CA) as described previously.
17-18
From CD34- fraction, CD14+ monocytes were separated using
an anti-CD14 monoclonal antibody (mAb) coupled to magnetic
beads (CD14 MicroBeads) followed by magnetic cell sorting
(MACS) column separation.
Purified CD34+ HSCs and CD14+ monocytes were cultured
with RPMI-1640 supplemented with 10% FBS, antibiotics and
L-glutamine (all from Gibco, Grand Island, NY) in the
presence of various combinations of 3 hematopoietic cytokines,
flt-3 ligand (FL), stem cell factor (SCF) and thrombopoietin
(TPO) (10 ng/ml each, all from Peprotech, Rocky Hill, NJ) for
6 days. After culture cells were harvested and counted for cell
proliferation.
2.2 Flow Cytometric Analysis
For flow cytometry, cells were stained with various
monoclonal antibodies (mAbs) or isotype control antibodies, for
15 min at 4
oC in the dark. FITC- or PE-conjugated monoclonal
antibodies with the following specificities were used: IgG1 and
IgG2a isotype controls, anti-CD34, -CD38, -CD45 and anti-
CD14 (all from BD Biosciences, San Jose, CA). Cells were
washed in PBS and then fixed in PBS containing 1%
paraformaldehyde. For data analysis, a Cytomics™
 flow
cytometer (Beckman Coulter, Fullerton, CA) was used. The data
were analyzed by WinMDI 2.8 (Scripps Institute, La Jolla, CA)
or CXP and FCS 3.0 software for the FC500 (Beckman Coulter). 
2.3 Cell Labeling
Freshly isolated CD14+ monocytes were stained with either
20 µM of with Cell Tracker Red CMTPX and CD34
+ cells
were stained with 0.15 µM of Cell Tracker Green CMFDA
(Molecular Probes, Eugene, OR), respectively, for 1 hr at 37
oC
according to the manufacturer’s instructions. The cells were
then washed 3 times with PBS.
2.4 Mice and Tumor Model
All procedures were reviewed and approved by the
Institutional Animal Care and Use Committee of Yonsei
University Severance Hospital, Seoul, Korea. HPac cells, a
human pancreatic adenocarcinoma cell line (ATCC, 8×10
6 cells
in a volume of 100 µl), were transplanted subcutaneously into the
back of female athymic nude mice (Orient, Seongnam, Korea) 6
to 8 weeks old and 17 to 20 g in weight. Seven days after
implantation, the fluorescent dye tagged cells (5×10
5 cells/
mouse, n=3) were injected to the tumor site. Animals with
tumors implanted but injected with PBS instead of human cells
served as control. Ten days later, the animals were sacrificed,
and tumor were removed and fixed in 10% phosphate-buffered
formalin and embedded in paraffin or immediately frozen in
isopentane in liquid N2 for later inclusion in OCT compound.
2.5 Confocal Fluorescence Microscopic Analysis
Sections of 5 µm were examined under a fluorescent
microscope to visualize the incorporation of the fluorescent-
labeled cells into the capillary networks. Frozen sections (10 µm
thick) of the tumor were subjected to immunohistochemistry, in
which the slides were incubated with mAb to human-specific
anti-factor VIII (BD Biosciences) followed by incubation with
PE-conjugated secondary antibody (BD Biosciences). Nuclei
were counterstained with DAPI (Sigma, St. Louis, MO). These
slides were examined with a confocal laser fluorescence
microscope. The proportions of CD34+ HSC-derived (CMFDA-
stained green fluorescent cells) cells and blood vessels
containing human factor VIII-expressing endothelial cells (PE-
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stained) were measured by optical density at 492 nm and
540 nm, respectively. 
2.6 Statistical Analysis
Data were analyzed using Student's t-test and unpaired t-test
with Welch’s correction. P-value < 0.05 was considered to be
statistically significant. 
3. Results
3.1 Phenotypes of Isolated CD14
+
 Monocytes and
CD34
+
 Hematopoietic Stem Cells
CD34+ cells typically represent less than 0.1% of human
PBMCs and flow cytometry analysis of purified cells showed
that more than 95% of the selected cells were positive for
CD34. CD14+ cells were selected from total CD34- PBMCs to
obtain an essentially pure population of CD14+ cells (Fig 1). In
parallel, analysis of expression of CD34 on CD14+ monocytes
and CD14 on CD34+ cells revealed that these markers are
mutually exclusive. MACS purified CD14+ cells (> 98 %
purity) contained little or no CD34 + cells (average 0.41±0.28,
mean±SD, n=5).
Next, we evaluated the growth promoting activities of
hematopoietic growth factors on the purified monocytes and
HSCs to exclude a possibility of HSC contamination in the
purified CD14
+ cells that may participate neoangiogenesis in
vivo (Fig 2). These growth factors, alone or in combinations,
had little effect on monocyte proliferation. On the contrary,
CD34
+ HSCs displayed different responses to the growth
factors. Little or no donor-to-donor variability was observed in
these assays. 
3.2 In Vivo Vasculogenic Properties of CD34
+
 HSCs
and CD14
+
 Monocytes
To determine whether CD34+ HSCs and CD34-CD14+
monocytes contribute to the tumor vasculature, human
pancreatic adenocarcinoma cell line HPac was implanted
subcutaneously into nude mice, and 7 days later freshly isolated
fluorescein-labeled CD34+ HSCs or CD14+ monocytes were
injected intratumorally at a dose of 5×105 cells/mouse. At day
10 after tumor inoculation, the mice were sacrificed. No
fluorescent cells were detected in tumors, liver or spleen from
mice injected with PBS (data not shown). On the other hand,
tumor sections obtained 10 days after transplantation from the
green fluorescent CD34+ cell-transplanted mice showed many
blood vessels carrying erythrocytes (Fig 3A). Transplanted
Figure 1. Isolation of CD14+ monocytes and CD34+ hematopoietic stem cells from human peripheral blood. Cells isolated by MACS
were stained with the indicated antibodies and analyzed by flow cytometer. CD34+ cell content of MACS-purified CD14+ cells were
determined by FACS analysis. Less than 0.1% of freshly isolated CD14+ cells had the progenitor marker CD34 and about 0.6% of iso-
lated CD34+ cells expressed the monocyte marker CD14. Numbers represent % of cells in each quadrant.
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cells were detected in abundance and had organized to form
vascular structures. In contrast, only a few vessels were seen in
the tumor sections from the red fluorescent CD14
+ monocytes
cell transplanted mice implying that vasculogenic potential of
CD34
+ HSCs in vivo was superior to that of CD14+ monocytes.
To test whether the combination of CD34
+ HSCs and CD14+
monocytes could synergize in neovascularization, equal
numbers of CD34
+ admixed with CD14+ monocytes were
injected intratumorally. Mixed EPC transplantation improved
vessel formation compared with any single type of EPC
transplantation. The mixed transplantation group had greater
capillary density than any group receiving single cell
transplantation. 
All the tumors were then stained with human-specific Factor
VIII. Tumors obtained from the mice that received CD34+
HSCs had blood vessels that included cells strongly expressing
human-specific factor VIII (Fig 3B). Many of the factor VIII-
positive vessels co-localized with green fluorescent cells (i.e.,
CD34+ HSC-derived). In contrast, tumors obtained from the
mice that received CD14+ monocytes had blood vessels that
included cells only weakly expressing factor VIII. Tumors
obtained from the mice that received the combination of CD34+
HSCs and CD14+ monocytes had blood vessels that included
cells strongly expressing factor VIII with higher density
compared to that of tumor received CD34
+ HSCs or CD14+
monocytes. These findings indicate that human monocytes
contributed to tumor vasculogenesis in vivo by being
incorporated and differentiating into the endothelium or to
pericytes.
To quantify dye-labeled cells in the tumor, we assessed
semiquantitatively the number of human cells in the tumor
blood vascular networks by spectrophotometer (Fig 4).
Intratumoral injection of any single type of cells led to
comparable neovascularization, both of which were better than
that of control. However, tumors in mice receiving CD14
+ and
CD34
+ cells had significantly more incorporated human cells in
the examined vessels than did tumors from mice receiving
CD34
+ HSCs or CD14+ monocytes alone. These results
demonstrated that both a fraction of human CD34
+ HSCs and
CD14
+ monocytes participate in the formation of human
pancreatic cancer vascularture and the combination of CD34
+
HSC and CD14+ monocytes significantly enhanced the
formation of new blood vessels. 
4. Discussion
Previous studies showed that there are different types of EPCs
present in the human peripheral blood.
19-20 Transplantation of
purified CD34
+ HSCs or ex vivo endothelial lineage-
differentiated cells of derived from human CD34
+ hematopoietic
stem cells (HSCs) incorporated into newly formed vessels in
animal ischemic models or in tumor angiogenesis.
21-23 Although
it has been shown that monocytes generate EPCs and exhibit
vascularizing properties in vitro
24 as well as in vivo,22,25 they are
considered as terminally differentiated cells and there is still no
direct proof of their possible “stemness” or of their relationships
with endothelium derived from CD34+ cells. Circulating
monocytes may promote the angiogenesis of EPCs indirectly
through soluble factor secretion.26 However, their source, stem
cell nature and the possible contribution of monocytes in the
HSC-driven angiogenesis was not clearly defined. The
proangiogenic effect of myeloid infiltrates27 and the
multipotency of CD14+ monocytes 28 prompt us to investigate the
role of monocytes in neovascularization. 
Here, we confirmed that freshly isolated human peripheral
blood CD34+ HSCs and CD14+ monocytes can participate in
tumor neoangiogenesis after intratumoral injection in nude
mouse that had received human HPac tumor cells. In addition
to endothelial differentiation from CD34+ HSCs, we confirmed
that CD14+ fraction can differentiate to factor VIII-expressing
endothelial cells in vivo. Integration of freshly isolated and
Figure 2. ell proliferation of CD14+ monocytes and CD34+ HSCs
by hematopoietic stem cell factors. Proliferation of cells in the
absence (M for media) or in the presence of three hematopoietic
growth factors, flt-3 ligand (F), thrombopoietin (T) and stem cell
factor (S) alone or in combinations, were measured. The cytokine
concentrations were fixed at 10 ng/ml each. Cells (1× 105 cells/
well) were cultured with the indicated cytokine combinations for
6 days and enumerated with hemocytometer. The results are
expressed as mean±SD of triplicates. *p < 0.05, **p < 0.01 and
***p<0.005.
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undifferentiated HSCs into blood vessels in vivo implies that
differentiation of precursor cells to endothelial cell is driven by
the tumor microenvironment. While CD14
+ monocytic EPCs
promote tumor neovasculogenesis, they do so less well than
their CD34+ EPC counterparts. However, combination of
CD34+ HSCs and CD14+ monocytes cooperated to enhance
neovasculogenesis in the human tumor in the nude mice. It has
been shown that circulating monocytes play a key role in
neovascularization29-30 and an infusion of bone marrow-derived
CD14+ monocytes contributes to the regeneration of functional
endothelium.31 Our findings are consistent with these reports
showing that CD14+ monocytes are not solely immune cells but
also potential precursors for endothelium. 
Different EPC subsets can influence the function of other
subsets, and the combination of these subsets can be beneficial
for enhanced neovascularization than using one subset alone.32 In
addition, the function of CD34+ HSCs is severely compromised
in certain pathological conditions such as diabetes. In this case,
Figure 3. Injected CD34+ HSC and CD14+ monocytes differentiate into endothelial cells in expanding tumor vessel network. (A) Puri-
fied CD34+ cells and CD14+ cells were labeled with CMFDA and CMTPX, respectively, and injected intratumorally into nude mice with
HPac tumors. Confocal images with hematoxylin and eosin staining of the tumor of PBS-injected control (a,b), CMFDA-labeled CD34+
cell-injected tumor (c,d), CMTPX-labeled CD14+ cells-injected tumor (e,f) and CMFDA-labeled CD34+ cell and CMTPX-labeled
CD14+ cells-injected tumor (g,h) reveal vessels with blood cells. Scale bar indicates 20 µm, initial magnification ×20. (B) Injected
CD34+ HSC and CD14+ monocytes differentiate into human factor VIII-expressing endothelial cells in tumor vessels. Purified CMFDA-
labeled CD34+ cells and unlabeled CD14+ cells were and injected intratumorally, alone or in combination, into nude mice with HPac
tumors. Confocal images of PBS-injected tumor (a,b), CD34+ cell-injected tumor (c,d), unlabeled CD14+ cells-injected tumor (e,f) and
mixed population of CMFDA-labeled CD34+ cell and unlabeled CD14+ cells-injected tumor (g,h) with human factor VIII-specific cells
(PE-conjugated secondary antibody) show vessels of human cell origin. Scale bar indicates 20 µm, initial magnification ×100. The
Arrowheads show RBCs associated with blood vessels.
Figure 4. Combination of CD34+ HSC and CD14+ monocytes
generates more human factor VIII-expressing cells in HPac
tumor of nude mice. The quantitation of human Factor VIII-
expressing endothelial cells in the tumor sections was spectro-
photometrically analyzed from the fluorescent images. **p <
0.01 and ***p<0.005.
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EPCs of CD14+ monocyte origin can be of a therapeutic
alternative.
33-34
 CD14+ cell-based therapy may be feasible in an
acute setting, as large quantity of CD14
+ monocytes can be easily
isolated with no pre-activation when directly injected into the
affected tissue.
In conclusion, the transplantation of mixed EPCs (of CD34
+
HSC and CD14+ monocytic) results in synergistic augmentation
of angiogenesis in athymic nude mice with human tumor. Such
synergistic interactions may also be present among other types of
stem or progenitor cells that may shed light on the future
direction of stem cell therapy. Our data indicate that local
injection of small numbers of freshly isolated circulating EPCs
can integrate to the tumor-induced vasculature, but that CD34
+
HSCs are more effective than CD14+monocytes in doing so. The
different roles played by two types of EPC in vasculogenesis
would be an interesting topic for a future study.
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